Uridine, Cytidine-5-monophosphate disodium salt

Pharmacological properties

The activity of celtican is due to phosphate groups, which are necessary for the connection of monosaccharides with ceramides to form cerebrosides and phosphatidic acids, which are the basis of sphingomyelin and glycerophospholipids. sphingomyelin and glycerophospholipids are the main components of the myelin sheath. Thus, when using the drug Keltican, an increase in the severity of trophic properties is achieved for the maturation and regeneration of axons of the nervous tissue.

Indications

Treatment of neuropathy of the osteoarticular (sciatica, radiculitis), metabolic (diabetic, alcoholic polyneuropathy), infectious (shingles) origin, as well as inflammation of the facial nerve, trigeminal nerve, intercostal neuralgia and lumbalgia.

Application

The drug is administered orally, regardless of food intake. adults: the recommended dose is 1-2 capsules 2 times a day.

The duration of the course of treatment is determined by the doctor individually.

Contraindications

Hypersensitivity to the components of the drug.

Side effects

Not described. however, hypersensitivity reactions may occur.

special instructions

During pregnancy and breastfeeding. the drug during pregnancy and lactation is used after a careful assessment of the benefit / risk ratio, since there is no data on the safety of the drug during pregnancy and lactation.

Children. The drug is not used in children.

The ability to influence the reaction rate when driving vehicles and working with other mechanisms. Keltikan does not affect the ability to drive vehicles and work with complex mechanisms.

Interactions

Not installed.

Overdose

Given the low toxicity of the drug, the reliability of poisoning is very low even if the therapeutic dose is accidentally exceeded. in case of overdose, symptomatic treatment.

Storage conditions

At a temperature not exceeding 30 ° C.

UA / CVM / 1018/0009